open access

Vol 7, No 2 (2004)
Published online: 2004-06-02
Submitted: 2012-01-23
Get Citation

The value of estimating serum aproptotic marker concentrations in monitoring and prognosis of 131I-therapy in Graves’ disease. Preliminary report

Franciszek Rogowski, Adam Parfieńczyk, Antoni Sopotyk, Tadeusz Budlewski, Ewa Jabłońska, Beata Kiersnowska-Rogowska, Piotr Szumowski
Nucl. Med. Rev 2004;7(2):117-122.

open access

Vol 7, No 2 (2004)
Published online: 2004-06-02
Submitted: 2012-01-23

Abstract

BACKGROUND: The effect of radioiodine (131I) in Graves’ disease (GD) is probably due to the direct physical destruction of thyrocytes by beta radiation, and by the indirect action through stimulation of apoptosis in these cells. The aim of our study was to investigate the changes in serum concentrations of sFas and sFasL as stimulators of apoptosis, and Bcl-2 as an inhibitor of apoptosis in patients with GD following 131I administration.
MATERIAL AND METHODS: The study was performed on 30 patients with GD (29 female and 1 male aged 25-45). All patients were euthyroid (biochemical and clinical) prior to radioiodine therapy. The target absorbed dose ranged between 90 and 160 Gy. We assessed markers of apoptosis and hormone concentrations (fT3, fT4 and TSH) in the following manner: before 131I administration, then two weeks, one month, two, three, four, and five months after 131I administration.
RESULTS: After four months, the concentrations of sFas and sFasL rose by 50% and decreased during the next month. Pretherapeutic concentrations of Bcl-2 were elevated, and peaked two weeks after ingestion, showing a gradual decrease with time. We found a significant increase in serum TSH, and a decrease of fT3 and fT4 concentrations by the end of the third month of radioiodine therapy.
CONCLUSIONS: Decreases in serum levels of sFas and sFasL and increases of Bcl-2 are regarded as characteristic for GD patients before radioiodine therapy. Radioiodine therapy reverses the ratio of estimated markers after four months. The concentrations of hormones reflect actual thyroid function, whereas concentrations of markers of apoptosis may suggest morphological changes.

Abstract

BACKGROUND: The effect of radioiodine (131I) in Graves’ disease (GD) is probably due to the direct physical destruction of thyrocytes by beta radiation, and by the indirect action through stimulation of apoptosis in these cells. The aim of our study was to investigate the changes in serum concentrations of sFas and sFasL as stimulators of apoptosis, and Bcl-2 as an inhibitor of apoptosis in patients with GD following 131I administration.
MATERIAL AND METHODS: The study was performed on 30 patients with GD (29 female and 1 male aged 25-45). All patients were euthyroid (biochemical and clinical) prior to radioiodine therapy. The target absorbed dose ranged between 90 and 160 Gy. We assessed markers of apoptosis and hormone concentrations (fT3, fT4 and TSH) in the following manner: before 131I administration, then two weeks, one month, two, three, four, and five months after 131I administration.
RESULTS: After four months, the concentrations of sFas and sFasL rose by 50% and decreased during the next month. Pretherapeutic concentrations of Bcl-2 were elevated, and peaked two weeks after ingestion, showing a gradual decrease with time. We found a significant increase in serum TSH, and a decrease of fT3 and fT4 concentrations by the end of the third month of radioiodine therapy.
CONCLUSIONS: Decreases in serum levels of sFas and sFasL and increases of Bcl-2 are regarded as characteristic for GD patients before radioiodine therapy. Radioiodine therapy reverses the ratio of estimated markers after four months. The concentrations of hormones reflect actual thyroid function, whereas concentrations of markers of apoptosis may suggest morphological changes.
Get Citation

Keywords

Graves’ disease; 131I therapy; apoptosis

About this article
Title

The value of estimating serum aproptotic marker concentrations in monitoring and prognosis of 131I-therapy in Graves’ disease. Preliminary report

Journal

Nuclear Medicine Review

Issue

Vol 7, No 2 (2004)

Pages

117-122

Published online

2004-06-02

Bibliographic record

Nucl. Med. Rev 2004;7(2):117-122.

Keywords

Graves’ disease
131I therapy
apoptosis

Authors

Franciszek Rogowski
Adam Parfieńczyk
Antoni Sopotyk
Tadeusz Budlewski
Ewa Jabłońska
Beata Kiersnowska-Rogowska
Piotr Szumowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl